secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001680367-25-000056
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q3 net loss $10.1M; SL-325 Phase 1 dosing underway; $103M private placement
--------------------------------------------------------------------------------

- First participants dosed in Phase 1 trial of SL-325 (DR3 antagonist) in healthy volunteers; SAD/MAD enrollment expected Q2 2026.
- Closed $103M private placement in August 2025; cash runway extended into 2029 assuming full warrant exercise.
- Net loss $10.1M ($0.14/sh) vs $16.6M ($0.33/sh) in Q3 2024; R&D expenses down to $7.6M from $16.3M.
- Appointed Dan Baker, M.D. and Mona Ashiya, Ph.D. to Board of Directors in August 2025.
- Cash and equivalents $86.1M as of Sept 30, 2025; funding to support SL-325 through Phase 2 and other milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000056/0001680367-25-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000056/sttk-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001680367-25-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer